



To: {Ordering Physician Last Name}
From: NeoGenomics NCI-MATCH Trial Team
Date: {Sent Date}
Subject: NCI-MATCH Potential Patient Eligibility for {NTP Case Number}

Dear Dr. {Ordering Physician Last name},

NeoGenomics has detected one or more alterations that may qualify your patient to receive targeted treatment on the NCI-MATCH trial. As a courtesy, this email is to inform you that your patient may be eligible to enroll for treatment in the clinical trial [NCI-MATCH \(EAY131\): Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma.](#)

NCI-MATCH is a phase two precision medicine trial being offered at your healthcare facility.

If you are not the primary oncologist, please forward to the appropriate treating physician.

Patient Information:

Patient: {NTP Case Number}

Genes with qualifying alteration(s): {gene/genes and alteration/alterations}

Specimen ID: {Specimen ID Number}

NeoLINK Results Portal: (<https://lis.neogenomics.com>)

If you do not have a username and password for NeoLINK, please contact our client services team by phone (866.776.5907, option 3) or e-mail (Client.Services@neogenomics.com).

General Information about NCI-MATCH trial:

NCI-MATCH is a phase two precision medicine trial being conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), with sponsorship from the National Cancer Institute (NCI). The trial is evaluating the effectiveness of treatment that is directed by genomic profiling in patients with solid tumors, lymphomas or myelomas that have progressed

following all standard treatments expected to prolong overall survival or for which there is no standard treatment. The study attempts to demonstrate that matching certain drugs or drug combinations to specific gene abnormalities harbored by a patient's tumor will effectively treat their cancer, regardless of its type.

This email is within the context of a collaboration agreement between NeoGenomics and the NCI, being implemented by ECOG-ACRIN in its role as trial leader. NeoGenomics' comprehensive and highly-validated genomic profiles are particularly sensitive to these rare alterations and well-suited to identifying treatment options like the NCI-MATCH trial for your patients.

NeoGenomics has detected one or more alterations that may qualify your patient to receive targeted treatment on the NCI-MATCH trial. If you are interested in this trial for your patient, we can connect you to your site's NCI-MATCH study coordinator(s) and/or principal investigator.

Website resources:

NeoGenomics: www.neogenomics.com/nci-match

ECOG-ACRIN: <http://ecog-acrin.org/nci-match-eay131>

NCI: www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match

Contact Information for MATCH investigators at your site:

<https://clinicaltrials.gov/ct2/show/study/NCT02465060#contacts>

If you have any questions regarding the availability of a referral for another patient, please contact NeoGenomics.

Sincerely,

NeoGenomics NCI-MATCH Trial Team
31 Columbia, Aliso Viejo, CA 92656 USA
Phone: 866.766.5907, ext. 3
Fax: 239.690.4237
E-mail: NCI-MATCH@NeoGenomics.com